Study drug RMC-9805 for patients with KRAS G12D solid tumors (RMC-9805-001) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if an investigational drug called RMC-9805 (the study drug) is a safe and effective option for treating KRAS G12D mutated cancer. We are also trying to figure out what dose of the study drug works best for most people.
What is the Condition Being Studied?
Solid Tumors With KRAS G12D Mutation
Who Can Participate in the Study?
Adults ages 18+ who:
- Have solid tumor(s) that are locally advanced or metastatic
- Have a documented KRAS G12D mutation
- Have worsened following standard therapy
Para obtener más información sobre quién puede unirse a este estudio, comuníquese con el equipo del estudio al 919-668-1861.
Grupo etario
Adultos
Study Details
Full Title
[RMC-9805-001] Phase 1/1b, multicenter, open-label, study of RMC-9805 in participants with advanced KRASG12D-mutant solid tumors
Principal Investigator
Especialista en oncología médica
Protocol Number
IRB:
PRO00114818
NCT:
NCT06040541
Phase
Fase I
ClinicalTrials.gov
View on ClinicalTrials.gov
Estado de inscripción
Abierto para inscripción
Participate
Call 919-668-1861
or email gi-oncology-cru@dm.duke.edu